Pelthos Therapeutics annual gross margin
2025
Pelthos Therapeutics's gross margin was 76.25% for fiscal 2025.
View full Pelthos Therapeutics company overview| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 76.25% | — |
| Fiscal quarter | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 76.86% | — |
| Q1 2026 | 2026-03-31 | 84.66% | — |
| Q4 2025 | 2025-12-31 | 89.87% | — |
| Q3 2025 | 2025-09-30 | −687.76% | — |
The latest reported quarter, Q2 2026, shows 76.86%.
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Pelthos Therapeutics source filings ↗